Dr. Jonathan Joseph Eskenazi, MD

Dr. Eskenazi practices at Neurological Institute of Los Angeles in Los Angeles, California.

Dr. Eskenazi's NPI, 1568894988, was assigned on August 8, 2013. Dr. Eskenazi graduated from Cayetano Heredia University in 2011. Dr. Eskenazi holds California license A140464.

Dr. Eskenazi's primary practice is Neurological Institute of Los Angeles, at 6363 W Wilshire Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 933-4590.

Dr. Eskenazi's primary practice is Neurological Institute of Los Angeles in Los Angeles, California. Dr. Eskenazi is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Neurological Institute of Los Angeles. Dmand AI also links Dr. Eskenazi to 2 more hospitals, 3 home health agencies, 2 group practices and clinics, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eskenazi practices, 9 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Eskenazi's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Eskenazi is board certified in physical medicine & rehabilitation by the American Board of Physical Medicine and Rehabilitation. Dmand AI has Dr. Eskenazi's licenses on file in 8 states: California, Florida, Nevada, Georgia, Texas, Arizona, Colorado and Ohio.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, encephalopathy, epilepsy, essential tremor and fibromyalgia and chronic pain among the conditions Dr. Eskenazi treats.

CMS data shows 17,963 Medicare services from Dr. Eskenazi across 32 procedure codes in 2024, for 1,816 Medicare patients. Medicare paid $2,473,376 for them.

CMS counts 1,816 Medicare patients who saw Dr. Eskenazi in 2024. The largest group is 65 to 74, with 751 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 84% are also on Medicaid. Their average risk score is 2.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Eskenazi's median patient age at 57, with 63% women.

In 2024, Dr. Eskenazi wrote 19,403 Medicare Part D claims for 2,972 patients. 87% of them were for generic drugs. CMS names the drug for 18,964 of them, across 101 drugs with 11 or more claims each, at $15,945,697 in total drug cost. In 2023, CMS named 14,983 claims across 97 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Eskenazi for performance year 2024, reported individually. Dr. Eskenazi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Eskenazi as offering telehealth.

Dmand AI links 8 papers to Dr. Eskenazi, published from 2020 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Multiple Sclerosis and Stroke. Dr. Eskenazi has published most often in Cureus. Dr. Eskenazi's most frequent co-authors are Regina R. Berkovich, MD, Antonio K. Liu, MD and Perminder J S Bhatia, MD.

Dmand AI links Dr. Eskenazi to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Constipation and Signs and Symptoms, Digestive. Enterin Inc. sponsors the most, 2.

CMS Open Payments shows 1,739 general payments to Dr. Eskenazi from 82 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 47% of the total. Abbvie Inc. paid the most, $29,835.

Dr. Eskenazi graduated from Cayetano Heredia University in 2011.

Dr. Eskenazi is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.